Eli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout

Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial

Eli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout